Bonny Deal: Wyeth Acquires Scottish Drug Discovery Firm Haptogen
This article was originally published in The Pink Sheet Daily
Firm hopes to use Haptogen’s technology to generate novel protein therapeutics that can be made orally bioavailable, VP-Biologic Technologies Projan tells “The Pink Sheet” DAILY.
You may also be interested in...
Pfizer's latest partnership in the space is with Theraclone Sciences, a Seattle start-up with an antibody technology that uses human B cells.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.